{"entity":{"id":"nct06072131","kind":"trial","name":"To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL","aka":[],"tldr":"A phase 3 trial of Belinostat and Pralatrexate in peripheral T-cell lymphomas, run by Acrotech Biopharma Inc., now recruiting.","summary":"To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL is a phase 3 interventional study registered as NCT06072131 by Acrotech Biopharma Inc., with 504 participants planned, started 2023-10-04 and due to reach its primary completion in 2030-07. Interventions recorded: Belinostat Injection, Pralatrexate Injection, CHOP and COP.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06072131","url":"https://clinicaltrials.gov/study/NCT06072131"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["peripheral-t-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["belinostat","pralatrexate"],"companies":["acrotech-biopharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06072131","phase":"3","setting":"A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients With Peripheral T-Cell Lymphoma","sponsor":"Acrotech Biopharma Inc.","enrolled":504,"outcomes":[]},"route":"/trials/nct06072131/","neighbours":{"cancer":[{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"}],"drug":[{"id":"belinostat","kind":"drug","name":"Belinostat","route":"/drugs/belinostat/"},{"id":"pralatrexate","kind":"drug","name":"Pralatrexate","route":"/drugs/pralatrexate/"}],"company":[{"id":"acrotech-biopharma","kind":"company","name":"Acrotech Biopharma","route":"/companies/acrotech-biopharma/"}]}}